STAT+: Early results for Alterome’s KRAS drug for pancreas, lung and colon cancer arrive
Both are already offering compounded drugs and eyeing BPC-157 and TB-500, two of six unapproved peptides covered by a new HHS policy easing enforcement against compounding pharmacies, STAT’s Sarah Todd and Katie Palmer write.
- Continue to STAT+ to read the full story….
- Want to stay on top of the science and politics driving biotech today?
- Sign up to get our biotech newsletter in your inbox.
Hims and Noom take peptides further into mainstream Hims & Hers and Noom are getting into the synthetic peptide business, bringing treatments marketed for muscle maintenance, intimacy, and longevity to a much larger audience — often with little evidence to support those uses.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →